Radiopharmaceuticals for therapy. (2016)

• Record Type: Book
• Further Information: Note: F. F. (Russ) Knapp, Ashutosh Dash.
• Authors: Knapp, Furn F, 1944-; Dash, Ashutosh
• Contents: Foreword; Acknowledgments; Contents; Abbreviations; Part I: Radiopharmaceuticals; 1: Introduction: Radiopharmaceuticals Play an Important Role in Both Diagnostic and Therapeutic Nuclear Medicine; 1.1 Introduction: Use of Radioisotopes in Nuclear Medicine; 1.2 Key Examples of Nuclear Medicine; 1.2.1 Nuclear Medicine Imaging; 1.2.2 Molecular Imaging; 1.2.3 In Vivo Function Tests; 1.2.4 Nuclear Medicine Therapy; 1.3 Radiopharmaceuticals; 1.3.1 Diagnostic Radiopharmaceuticals; 1.3.2 Nuclear Medicine Imaging; 1.3.2.1 Planar Imaging. 1.3.2.2 Single-Photon Emission Computed Tomography (SPECT)1.3.2.3 Positron Emission Tomography (PET); 1.4 Therapeutic Radiopharmaceuticals; 1.4.1 Traditional Applications of Therapeutic Radiopharmaceuticals; 1.4.2 Current and New Therapeutic Applications; 1.4.2.1 Peptide Receptor Radionuclide Therapy (PRRT); 1.4.2.2 Radioimmunotherapy; 1.4.2.3 Treatment of Hepatocellular Carcinoma (HCC) and Hepatic Malignancies; 1.4.2.4 Bone Pain Palliation Therapy; 1.4.2.5 Nonmelanoma Skin Cancer Therapy; 1.4.2.6 Radiosynovectomy: Therapy of Arthritis (Radiosynoviorthesis) 1.4.2.7 Therapy of Arterial Restenosis following Balloon Angioplasty1.5 Historical Timeline of Nuclear Medicine; 1.6 Summary; References; 2: Therapeutic Radionuclides Decay with Particle Emission for Therapeutic Applications; 2.1 Introduction; 2.2 Criteria for Selection of Therapeutic Radionuclides; 2.2.1 Particle Emission; 2.2.2 Tissue Treatment Morphology; 2.2.3 Radionuclide Half-Life; 2.2.4 Radionuclide Decay Products; 2.2.5 Radionuclide Purity; 2.2.6 Gamma Emissions; 2.2.7 Radiolabeling Chemistry; 2.2.8 Economic Factors; 2.3 Beta-Particle-Emitting Radionuclides. 2.4 Alpha-Particle-Emitting Radionuclides2.5 Low-Energy Electron Emitters; 2.6 Radionuclide Production; 2.6.1 Targets for Irradiation; 2.6.2 Production of Therapeutic Radionuclides; 2.6.3 Auger Electron-Emitting Radionuclides; 2.6.4 Alpha-Particle-Emitting Radionuclides; References; 3: Alpha Radionuclide Therapy; 3.1 Introduction; 3.2 Alpha Particles; 3.2.1 Energy Dissipation of Alpha Particles in a Medium; 3.2.2 Linear Energy Transfer (LET); 3.2.3 Relative Biological Effectiveness (RBE); 3.2.4 Interaction of Alpha Particles in a Biological System. 3.2.5 Basis of Alpha Radionuclide Therapy3.2.6 Dosimetry; 3.3 Alpha-Particle-Emitting Radionuclides for Radiotherapy; 3.3.1 Astatine-211; 3.3.1.1 Production of 211At; 3.3.1.2 Astatine Chemistry; 3.3.1.3 Astatine-211 Radiopharmaceuticals; Astatide (211At−); 211At-MIBG; 211At-Bisphosphonates; 211At-Peptides; Clinical Studies with 211At-Antibodies; 3.3.2 Terbium-149; 3.3.3 Actinium-225; 3.3.3.1 225Ac Decay Scheme; 3.3.3.2 Preclinical Studies with 225Ac; 3.3.4 Bismuth-213; 3.3.5 Bismuth-212; 3.3.6 Radium-223; 3.3.7 Radium-224; 3.3.8 Thorium-227.
• Publisher Details: New Delhi : Springer
• Publication Date: 2016
• Extent: 1 online resource (xxiv, 347 pages), illustrations (some color)
• Subjects: 615.8/42; Radiopharmaceuticals; MEDICAL / Pharmacology; Radiopharmaceuticals; Radiopharmaceuticals; Electronic books
• Languages: English
• ISBNs: 9788132226079; 8132226070
• Related ISBNs: 9788132226062; 8132226062
• Notes: Note: Includes bibliographical references.; Note: Online resource; title from PDF title page (SpringerLink, viewed January 27, 2016).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.